Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Snap Inc — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B), while Snap Inc trades at $5.89 (market cap $9.83B). The key difference: Snap Inc is far larger — about 4.3× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| SLS | SNAP | |
|---|---|---|
Market Cap | $2.28B | $9.83B |
Volume | 3,128,960 | 28,532,342 |
Sector | Health | Media |
52-Week High | $15.46 | $9.09 |
52-Week Low | $1.39 | $3.93 |
Enterprise Value | $2.15B | $11.39B |
Typical Hold Time | — | 68 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Snap Inc. (SNAP) trades at $5.865, up 1.12% with a bullish technical signal. Revenue grew to $5.93B in 2025, though net losses persist at -$460M. Recent news highlights AI integration in SPECS glasses via partnerships with NVIDIA and Salesforce. Analyst consensus is mixed with 38% buy ratings and a $7.78 price target.
Outlook: Potential upside exists from AI initiatives and revenue growth, but profitability challenges and high debt ($3.61B) pose risks. The stock's valuation (P/S 1.55) appears reasonable, yet investor caution is warranted amid regulatory pressures and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
